$CHRO News
Last published 1y ago
- 1y agoCHROPTHSPelthos Therapeutics Launches ZELSUVMI™ (berdazimer) Topical Gel 10.3%, the First and Only FDA-Approved At-Home Treatment for Molluscum ContagiosumGlobeNewswireZELSUVMI is now commercially available via prescription through retail pharmacies, ASPN pharmacy services and for at-home delivery through mail-order pharmaciesOnce-daily topical prescription medication can be applied by
- 1y agoCHROLGNDPelthos Therapeutics Completes Merger with Channel Therapeutics and Closes $50.1 Million Private PlacementGlobeNewswireThe combined company plans to launch ZELSUVMI™ for the treatment of molluscum contagiosum infections in July 2025 Concurrent with the closing of the merger, the combined company closed on a $50.1 million equity
- 1y agoCHROChannel Therapeutics Announces Reverse Common Stock Split in Conjunction with the Close of the Merger with Pelthos Therapeutics and Concurrent $50.1 Million Private PlacementGlobeNewswireFREEHOLD, N.J., June 27, 2025 (GLOBE NEWSWIRE) -- Channel Therapeutics Corporation, ("Channel" or the "Company"), (NYSE:CHRO), an emerging leader in the development of non-opioid pain treatment therapeutics, today
- 1y agoCHROChannel Therapeutics Announces Positive Efficacy Results for the Treatment of Eye Pain Using its NaV1.7 Inhibitor in Multiple Preclinical In Vivo ModelsGlobeNewswireFREEHOLD, N.J., May 14, 2025 (GLOBE NEWSWIRE) -- Channel Therapeutics Corporation, ("Channel" or the "Company"), (NYSE:CHRO), a pioneer in the development of non-opioid pain treatment therapeutics, today announced that
- 1y agoCHROChannel Therapeutics Provides Announcement on 2024 Annual Report to Comply with NYSE American Listing RulesGlobeNewswireFREEHOLD, N.J., May 01, 2025 (GLOBE NEWSWIRE) -- Channel Therapeutics Corporation, ("Channel" or the "Company"), (NYSE:CHRO), a pioneer in the development of non-opioid pain treatment therapeutics, today advises that,
- 1y agoCHROLGNDLigand Subsidiary Pelthos Therapeutics to Combine with Channel TherapeuticsGlobeNewswireProposed transaction will raise $50 million in equity capital and enhance a publicly traded biopharmaceutical company focused on launching Pelthos' ZELSUVMI™ ZELSUVMI is an FDA-designated novel drug and the first
- 1y agoCHROChannel Therapeutics Highlights Differences Between NaV1.7 and NaV1.8 in Light of Recent Clinical Data on SuzetrigineGlobeNewswireFREEHOLD, N.J., Dec. 20, 2024 (GLOBE NEWSWIRE) -- Channel Therapeutics Corporation, ("Channel" or the "Company"), (NYSE:CHRO), a pioneer in the development of non-opioid pain treatment therapeutics, is providing a
- 1y agoCHROChannel Therapeutics Announces Positive Efficacy Data For a Depot Formulation of a NaV1.7 Inhibitor in a Preclinical In Vivo Nerve Block ModelGlobeNewswireFREEHOLD, N.J., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Channel Therapeutics Corporation, ("Channel" or the "Company"), (NYSE:CHRO), a pioneer in the development of non-opioid pain treatment therapeutics, today announced
- 1y agoCHROChromocell Announces Name Change to "Channel Therapeutics Corporation" and Provides Therapeutic Program UpdatesGlobeNewswire"Channel Therapeutics" reflects the Company's focus on developing therapeutics to treat pain utilizing sodium channel blockade and modulationNew name is in advance of multiple near-term data readouts FREEHOLD, N.J.,
- 2y agoCHROChromocell Announces Unveiling of Injectable Depot Program for the Treatment of Surgical PainGlobeNewswireFREEHOLD, N.J., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corporation ("Chromocell", or the "Company"), (NYSE:CHRO), a pioneer in the development of non-opioid pain treatment therapeutics, today
- 2y agoCHROChromocell to Present at Upcoming Fall Investor ConferencesGlobeNewswireFREEHOLD, N.J., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corporation ("Chromocell", or the "Company"), (NYSE:CHRO), a pioneer in the development of non-opioid pain treatment therapeutics, today
- 2y agoCHROChromocell Announces Amendment to Stock Repurchase PlanGlobeNewswireFREEHOLD, N.J., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corporation ("Chromocell", or the "Company"), (NYSE:CHRO), a pioneer in the development of non-opioid pain treatment therapeutics, today
- 2y agoCHROChromocell to Participate in Life Sciences Investor Forum September 19thGlobeNewswireChromocell invites individuals, institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.com FREEHOLD, N.J., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics
- 2y agoCHROChromocell to Present at the H.C. Wainwright 26th Annual Global Investment ConferenceGlobeNewswireFREEHOLD, N.J., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corporation ("Chromocell", or the "Company"), (NYSE:CHRO), a pioneer in the development of non-opioid pain treatment therapeutics, today
- 2y agoCHROChromocell Announces Stock Repurchase PlanGlobeNewswireFREEHOLD, N.J., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corporation ("Chromocell", or the "Company"), (NYSE:CHRO), a pioneer in the development of non-opioid pain treatment therapeutics, today
- 2y agoCHROChromocell to Participate in the Virtual Investor Lunch Break SeriesGlobeNewswireFREEHOLD, N.J., July 15, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corporation ("Chromocell", or the "Company"), (NYSE:CHRO), a pioneer in the development of non-opioid pain treatment therapeutics, today
- 2y agoCHROChromocell To Present at Alliance Global Partner's Healthcare Company Showcase on Tuesday, May 21, 2024GlobeNewswireFREEHOLD, N.J., May 13, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corporation ("Chromocell", or the "Company"), (NYSE:CHRO), a pioneer in the development of non-opioid pain treatment therapeutics, today
- 2y agoCHROChromocell Issues Letter to Stockholders from Chief Executive OfficerGlobeNewswireFREEHOLD, N.J., April 09, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corporation ("Chromocell", or the "Company"), (NYSE:CHRO), a pioneer in the development of non-opioid pain treatment therapeutics, today
- 2y agoCHROChromocell Announces Formal Launch of Eye Pain Treatment Program and Hiring of Dr. Simon ChandlerGlobeNewswireFREEHOLD, N.J., March 21, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corp. ("Chromocell", or the "Company"), (NYSE:CHRO), a pioneer in the development of non-opioid pain treatment therapeutics, today announced
- 2y agoCHROChromocell Names Frank Knuettel as Chief Executive Officer, Removing Interim Status Held Since July 2023GlobeNewswireFREEHOLD, N.J., March 18, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corp. ("Chromocell", or the "Company"), (NYSE:CHRO), a pioneer in the development of non-opioid pain treatment therapeutics, today announced
- 2y agoCHROChromocell to Present at Sidoti Virtual Investor Conference March 13-14GlobeNewswireAUSTIN, Texas, March 11, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corp. ("Chromocell", or the "Company"), (NYSE:CHRO), a pioneer in the development of non-opioid pain treatment therapeutics, today announced
- 2y agoCHROBenuvia Operations, LLC and Chromocell Therapeutics Corp. Announce Strategic Partnership to Advance Healthcare SolutionsGlobeNewswireAUSTIN. Texas, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Benuvia Operations, LLC ("Benuvia"), a leader in pharmaceutical innovation, and Chromocell Therapeutics Corp. ("Chromocell"), (NYSE:CHRO), a pioneer in the development
- 2y agoCHROChromocell Therapeutics Announces Pricing of Upsized $6.6 Initial Public OfferingGlobeNewswireFREEHOLD, N.J., Feb. 16, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corporation (NYSE:CHRO) ("Chromocell" or the "Company"), a clinical-stage biotech company focused on developing and commercializing new,